Related Experiment Video

Updated: Jul 4, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Stem cell transplantation in children: how to design a new study

S Corbacioglu1,

  • 1Department of Paediatrics, University Children's Hospital, Ulm, Germany. selim.corbacioglu@uniklinik-ulm.de

Bone Marrow Transplantation
|July 24, 2008
PubMed

Insights

New European Union (EU) regulations impose strict good clinical practice (GCP) rules on investigator-initiated trials (IITs), potentially delaying crucial pediatric cancer treatments. Efforts are underway to ease these burdens and facilitate pediatric drug development.

Area of Science:

  • Pediatric Pharmacology
  • Clinical Trial Regulation
  • Oncology Drug Development

Background:

  • A significant proportion of medicines used in children lack specific pediatric studies within the EU.
  • New European Union (EU) directives mandate stringent good clinical practice (GCP) compliance for all clinical trials, including investigator-initiated trials (IITs).
  • This increased regulatory burden, while aiming for quality, poses substantial logistical, administrative, and financial challenges for principal investigators.

Purpose of the Study:

  • To analyze the impact of new EU regulations on investigator-initiated trials (IITs), particularly in pediatric oncology.
  • To highlight the challenges faced by principal investigators in complying with good clinical practice (GCP) for IITs.
  • To discuss the implications of these regulations on the timely implementation of innovative pediatric treatment strategies and to explore potential solutions.

Main Methods:

  • Review of EU directives and regulations concerning clinical trials, specifically Directive 2001/20/EG and Regulation (EC) no. 1901/2006.
  • Analysis of the administrative and logistical burdens imposed by GCP compliance on investigator-initiated trials (IITs).
  • Examination of the potential impact on pediatric oncology treatment optimization studies and drug development.

Main Results:

  • The ratification of EU Directive 2001/20/EG imposes significant GCP compliance burdens on IITs, akin to commercial trials.
  • These new requirements create substantial logistical, administrative, and financial challenges for principal investigators.
  • Treatment optimization studies in pediatric oncology are particularly affected, risking delays in adopting new therapies.

Conclusions:

  • While aiming to improve clinical trial quality, current EU regulations present significant hurdles for IITs, potentially impeding pediatric drug development.
  • Recent legislative measures, including draft guidance and Regulation (EC) no. 1901/2006, show promise but major challenges persist.
  • A coordinated, expert-driven approach is essential to support novice investigators in conducting pediatric IITs effectively and to facilitate the development of crucial medicines for children.

More Related Videos

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Culture01:17

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...